A new review of studies on the economic impacts of pharmacy benefit managers (PBMs) found that they have an adverse impact on the overall costs and prices of drugs.

“Pharmacy benefit managers impact more than 260 million Americans when they purchase their prescription drugs, but most people have no idea what they are, or the big impact they play in their health care,” said Wayne Winegarden, PhD, Senior Fellow in Business and Economics at the Pacific Research Institute (PRI) and author of the PRI’s report, “The Economic Costs of Pharmacy Benefit Managers: A Review of the Literature.” PRI is a free-market public policy think tank in San Francisco.

Continue Reading on Drug Topics